Growth Metrics

Incyte (INCY) Current Deferred Revenue: 2010-2016

Historic Current Deferred Revenue for Incyte (INCY) over the last 6 years, with Sep 2016 value amounting to $2.9 million.

  • Incyte's Current Deferred Revenue fell 77.69% to $2.9 million in Q3 2016 from the same period last year, while for Sep 2016 it was $2.9 million, marking a year-over-year decrease of 77.69%. This contributed to the annual value of $12.5 million for FY2015, which is 2.86% down from last year.
  • As of Q3 2016, Incyte's Current Deferred Revenue stood at $2.9 million, which was down 52.85% from $6.1 million recorded in Q2 2016.
  • Over the past 5 years, Incyte's Current Deferred Revenue peaked at $67.0 million during Q1 2012, and registered a low of $2.9 million during Q3 2016.
  • Its 3-year average for Current Deferred Revenue is $11.0 million, with a median of $12.9 million in 2015.
  • Data for Incyte's Current Deferred Revenue shows a maximum YoY plummeted of 80.49% (in 2013) over the last 5 years.
  • Over the past 5 years, Incyte's Current Deferred Revenue (Quarterly) stood at $66.1 million in 2012, then tumbled by 80.49% to $12.9 million in 2013, then dropped by 0.08% to $12.9 million in 2014, then declined by 2.86% to $12.5 million in 2015, then tumbled by 77.69% to $2.9 million in 2016.
  • Its Current Deferred Revenue was $2.9 million in Q3 2016, compared to $6.1 million in Q2 2016 and $9.3 million in Q1 2016.